Vigene Biosciences
Charles River acquired a cell and gene therapy CDMO business in June 2021 and has integrated those capabilities into its CDMO offerings. The organization provides contract development and manufacturing services for cell and gene therapies, including plasmid DNA, viral vector, and cell therapy manufacturing. The site states it has supported development of 15 FDA‑approved cell and gene therapies and conducted more than 1,000 studies in this field.
Industries
Nr. of Employees
medium (51-250)
Vigene Biosciences
Rockville, Maryland, United States, North America
Products
Plasmid and viral vector products
Reagent and vector products for use in cell and gene therapy research and manufacturing.
Plasmid and viral vector products
Reagent and vector products for use in cell and gene therapy research and manufacturing.
Services
Contract manufacturing of plasmid DNA for use in gene therapy development and manufacturing workflows.
Contract production and scale-up of viral vectors for gene delivery.
Manufacturing services for cell therapy products including production and process support.
Packaging and downstream handling services for viral vector products.
Supply of plasmid and viral vector reagents and products for research and manufacturing use.
Use of an integrated network of contract development and manufacturing sites and associated testing locations to support development and production.
Contract manufacturing of plasmid DNA for use in gene therapy development and manufacturing workflows.
Contract production and scale-up of viral vectors for gene delivery.
Manufacturing services for cell therapy products including production and process support.
Packaging and downstream handling services for viral vector products.
Supply of plasmid and viral vector reagents and products for research and manufacturing use.
Use of an integrated network of contract development and manufacturing sites and associated testing locations to support development and production.
Expertise Areas
- Cell and gene therapy CDMO services
- Plasmid DNA production
- Viral vector production and packaging
- Cell therapy manufacturing
Key Technologies
- Plasmid DNA manufacturing
- Viral vector production
- Viral vector packaging
- Cell therapy manufacturing
News & Updates
In June 2021 Charles River acquired a cell and gene therapy contract development and manufacturing business and integrated its website and capabilities.
Reported support in the development of 15 FDA‑approved cell and gene therapies.
Reported conduct of more than 1,000 studies in the cell and gene therapy field over the referenced time period.
In June 2021 Charles River acquired a cell and gene therapy contract development and manufacturing business and integrated its website and capabilities.
Reported support in the development of 15 FDA‑approved cell and gene therapies.
Reported conduct of more than 1,000 studies in the cell and gene therapy field over the referenced time period.